Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma
Recruiting
- Conditions
- Multiple Myeloma
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Target Recruit Count
- 80
- Registration Number
- NCT06302699
Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)
Phase 2
Recruiting
- Conditions
- Immune ThrombocytopeniaIdiopathic Thrombocytopenic Purpura
- Interventions
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2024-07-22
- Target Recruit Count
- 17
- Registration Number
- NCT06287567
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-02-24
- Target Recruit Count
- 60
- Registration Number
- NCT06281327
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia
Not Applicable
Recruiting
- Conditions
- AMLRefractoryRelapsed
- Interventions
- Drug: Ivosidenib,Venetoclax,gilteritinib,Selinexor
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-08-12
- Target Recruit Count
- 120
- Registration Number
- NCT06265545
- Locations
- 🇨🇳
Blood Hospital, Tianjin, China
Rituximab for Serious Aplastic Anemia With Platelet Transfusion Refractoriness
Phase 2
Recruiting
- Conditions
- Severe Aplastic AnemiaPlatelet Transfusion Refractoriness
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-02-12
- Target Recruit Count
- 20
- Registration Number
- NCT06254560
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Efficacy and Safety of Avatrombopag vs. Avatrombopag Combined With rhTPO in the Treatment of SAA
Phase 2
Not yet recruiting
- Conditions
- Anemia, Aplastic
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-02-12
- Target Recruit Count
- 60
- Registration Number
- NCT06254287
GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
Phase 2
Recruiting
- Conditions
- Peripheral T Cell LymphomaDiffuse Large B-cell Lymphoma
- Interventions
- Drug: GVM±R regimen
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2025-05-14
- Target Recruit Count
- 115
- Registration Number
- NCT06244368
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin, Tianjin, China
Safety and Efficacy Study of NGGT003 in Hemophilia A Patients
- First Posted Date
- 2024-02-02
- Last Posted Date
- 2025-02-21
- Target Recruit Count
- 6
- Registration Number
- NCT06238908
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin, China
CNCT19 for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy.
Phase 1
Active, not recruiting
- Conditions
- Failure of Three or More Lines of TherapyAutoimmune Hemolytic AnemiaAutologous CD19 CAR-T
- Interventions
- Biological: CNCT19 CAR-T cell therapy
- First Posted Date
- 2024-01-30
- Last Posted Date
- 2025-05-16
- Target Recruit Count
- 6
- Registration Number
- NCT06231368
- Locations
- 🇨🇳
Regenerative Medicine Center, Tianjin, Tianjin, China
Efficacy and Safety of Linperlisib in Relapsed/Refractory Large Granular T Lymphocytic Leukemia
Phase 2
Recruiting
- Conditions
- Relapsed/Refractory Large Granular T Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2024-01-25
- Last Posted Date
- 2024-01-25
- Target Recruit Count
- 41
- Registration Number
- NCT06224257
- Locations
- 🇨🇳
Zhoukou Central Hospital, Zhoukou, Henan, China
🇨🇳Regenerative Medicine Center, Tianjin, Tianjin, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
© Copyright 2025. All Rights Reserved by MedPath